Acme United Corp (ACU) · Oct 27, 2026 · Earnings
Beat — Diluted EPS $0.80 vs roughly $0.74 consensus; sales $58.0M vs ~$56.95M
ACME United earnings beat Q3 expectations on strong sales and My Medic growth, though tariff refunds and tax benefits make the profit surge less repeatable.
Acme United is in an acquisition-and-efficiency phase: it added the direct-to-consumer My Medic emergency-products business in January 2026 while consolidating manufacturing to offset rising freight and raw-material costs. The My Medic deal had a maximum purchase price of $18.7 million and was designed to add tactical and first-aid products to Acme’s portfolio.
| Metric | Q3 2026 | Q3 2025 / expectation |
|---|---|---|
| Net sales (News Release) | $58.0M | $49.1M; ~$56.95M consensus |
| Diluted EPS (Income Statement) | $0.80 | $0.46; ~$0.74 consensus |
| Net income (Income Statement) | $3.4M | $1.9M |
| Gross margin (News Release) | 45.3% | 39.1% |
| Bank debt less cash (News Release) | $29.7M | $23.1M |
The quarter beat expectations on both sales and EPS. Sales rose 18% year over year to $58.0 million, while comparable sales excluding My Medic increased 10%, showing that the result was not purely acquisition-driven. Published Q3 estimates were about $56.95 million of revenue and $0.69-$0.74 of EPS, so the company cleared the available benchmark, though the small-cap estimate base is limited.
The earnings beat is real but unusually helped by nonrecurring items. Acme received $6.0 million of tariff refunds and recognized $4.0 million in the quarter as a reduction of cost of goods sold. That benefit was partly offset by $1.0 million of related variable compensation and $1.8 million of DMT closure costs, but the refund still materially lifted reported gross margin and profit.
The underlying operating story improved beyond the refund. Gross margin excluding the tariff refund and DMT closure costs remained above last year, primarily because of the higher-margin My Medic direct-to-consumer business. My Medic contributed little profit in this quarter because its business is seasonal, with most profitability expected in the fourth quarter, so the bigger test is whether holiday demand converts the acquired sales base into earnings.
The cost-cutting plan adds a future margin lever, but also confirms ongoing pressure. Acme is closing its Massachusetts DMT sharpening facility and moving production and fulfillment elsewhere; the company expects more than $1.0 million of annual savings in 2027. At the same time, bank debt less cash rose to $29.7 million from $23.1 million as the company funded My Medic and other acquisitions, so the growth strategy is producing stronger sales with a somewhat heavier balance-sheet load.
Bottom line: This was a genuine earnings beat, supported by broad sales growth and early My Medic traction, but the profit quality is mixed because tariff refunds did much of the margin lifting. The next meaningful proof point is whether My Medic’s fourth-quarter seasonality and the DMT restructuring create durable earnings improvement.
My Medic holiday sales and 2027 DMT savings realization
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!